With its common shares frequently trading under the $5 threshold—often fluctuating around the sub-dollar to low-dollar range—Humacyte is technically classified by market definition as a penny stock or micro-cap equity. This status subjects the stock to higher intraday volatility, sensitivity to exchange compliance rules regarding minimum bid prices, and wider percentage swings compared to large-cap blue-chip corporations.